GlassScriptPhysician profile
John P Dice
NPI 1437140506
$18,701.90
in general payments reported to CMS, 2019-2025
38 companies · $4,071 in 2025
The $4,071 reported for 2025 was more than what 81% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,068 · 2020: $1,659 · 2021: $1,579 · 2022: $3,251 · 2023: $2,931 · 2024: $2,143 · 2025: $4,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,525 · Consulting Fee: $1,446 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,525.11 |
| Consulting Fee | $1,446.00 |
| Education | $174.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $3,860.61 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,235.65 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $2,501.30 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,886.23 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Sanofi-Aventis U.S. LLC | $1,562.06 | 2019-2025 | |
| Genentech USA, INC. | $654.15 | 2019-2025 | Xolair |
| Csl Behring | $492.96 | 2019-2024 | Haegarda, Hizentra |
| Novartis Pharmaceuticals Corporation | $492.90 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $441.70 | 2025 | Neffy |
| Alk-Abello, INC | $391.27 | 2019-2025 | Ragwitek, Odactra, Grastek |
| Kaleo, INC. | $359.53 | 2019-2024 | Auvi-Q |
| Incyte Corporation | $348.72 | 2022-2023 | Opzelura |
| Shire North American Group INC | $315.98 | 2019 | |
| Amgen INC. | $296.05 | 2020-2025 | Tezspire |
| Grifols USA, LLC | $264.13 | 2019-2023 | Xembify, Prolastin-C Liquid |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $236.04 | 2020-2025 | Cuvitru |
| Optinose US, INC. | $207.14 | 2019-2022 | |
| Pfizer INC. | $154.81 | 2020-2025 | |
| Phadia US INC. | $138.45 | 2024-2025 | Immunocap |
| Genentech, INC. | $128.64 | 2019 | |
| Octapharma USA, INC. | $125.00 | 2022-2023 | Cutaquig, Octagam Immune Globulin (Human) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.74 | 2019-2021 | |
| Pharming Healthcare, INC. | $73.66 | 2020-2024 | Ruconest |
| Jubilant Hollisterstier LLC | $47.16 | 2019 | |
| Organon LLC | $46.69 | 2025 | Vtama |
| Mylan Pharmaceuticals INC. | $45.23 | 2019-2020 | |
| Leo Pharma INC. | $39.67 | 2024-2025 | Adbry |
| Galderma Laboratories, L.P. | $38.03 | 2025 | Nemluvio |
| Lilly USA, LLC | $30.74 | 2024 | Taltz, Ebglyss |
| Greer Laboratories, INC. | $28.25 | 2023 | Palforzia |
| Aimmune Therapeutics, INC. | $27.24 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $27.08 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $21.33 | 2023 | Dupixent |
| Adma Biomanufacturing LLC | $20.91 | 2020 | |
| Horizon Therapeutics Plc | $17.64 | 2019 | |
| Merck Sharp & Dohme LLC | $16.97 | 2021 | |
| Hikma Pharmaceuticals USA | $16.24 | 2023 | Ryaltris |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.